The 2021 ASH Annual Meeting: CAR T-Cell Therapy priority report is a digital version of the print publication spanning some of the groundbreaking abstracts in CAR T-cell therapy that were presented during the conference.
December 15, 2021
Article
A single infusion of ciltacabtagene autoleucel produced an overall response rate of 95% in patients with multiple myeloma who had received a median of 2 prior lines of treatment and who were refractory to lenalidomide.
December 14, 2021
Article
Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.
December 13, 2021
Article
Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.
December 13, 2021
Article
Ciltacabtagene autoleucel elicited a 97.9% objective response rate and an 82.5% stringent complete response rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up.
December 13, 2021
Article
Treatment with lisocabtagene maraleucel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphomas.
December 11, 2021
Article
Tisagenlecleucel produced a high overall response rate and complete response rate in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial.
December 11, 2021
Article
Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.
December 11, 2021
Article
Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.